Gleneagles Hospital Hong Kong’s Peritoneal Malignancy Treatment Centre has introduced new intraperitoneal chemotherapy procedures, including Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC), to provide more effective treatment to patients with peritoneal cancer.
Dr Kenneth Tsang, Chief Executive Officer of Gleneagles Hospital Hong Kong, said, “In addition to our advanced radiotherapy facilities, we have also launched a centre dedicated to serving patients with peritoneal metastasis. Our experienced multidisciplinary medical team provides patients with comprehensive diagnostic services and personalised treatments.” The Centre is the first of its kind in Hong Kong catering to patients with peritoneal metastasis. Medical studies have found HIPEC to effectively improve the survival rate of patients with ovarian cancer, gastric cancer or colorectal cancer. The innovative PIPAC treatment is also known to relieve symptoms of peritoneal metastasis and reduce the side effects of chemotherapy, which helps improve the patient’s quality of life.
Related Stories
Mount Elizabeth Hospitals Celebrate 97 Wins at Singapore Health Quality Service Awards 2026
Celebrating the People of Gleneagles Hong Kong
Acibadem Powers Africa’s Premier Football Tournament
Gleneagles JPMC Supports the Children Cancer Foundation
Extending its corporate giving efforts, Gleneagles JPMC presented a cash donation of BND10,000 during its visit to the Yayasan Kanser Kanak-Kanak (YASKA).
Gleneagles Hospital Johor Opens International Lounge to Enhance Cross-border Care
